Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics
Imiquimod (trade name Aldara™) is a small molecule of the imidazoquinoline family, a group of nucleoside analogs that were first synthesized as potential antiviral agents. It has since been discovered to activate both innate and adaptive immunity, as well as apoptosis. Clinically, it has been approved for three indications thus far: external genital warts, actinic keratosis, and superficial basal cell carcinoma. In addition to these applications, a number of off-label uses have been reported in the literature. In this review, we summarize and discuss the literature describing imiquimod’s mechanism of action, its approved and off-label clinical uses, and its safety and tolerability.
PDF (672.64 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
It is my pleasure to confirm that we had a very pleasant experience by publishing our article in Clinical Medicine Insights: Therapeutics. The review process was highly efficient and the reviewers' comments useful and constructive. I am sure that this is the kind of publication needed by the scientific community. I am looking forward future collaborations.
Facebook Google+ Twitter
Pinterest Tumblr YouTube